ScholarIQanswers from OpenAlex & ORCID
Ricardo Correa‐Rotter
ResearcherPublications, citations & collaboration network
Ricardo Correa‐Rotter is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ricardo Correa‐Rotter have?
ScholarIQindexed works
Ricardo Correa‐Rotter has 311 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ricardo Correa‐Rotter have?
ScholarIQcitation count
Ricardo Correa‐Rotter has 19,453 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ricardo Correa‐Rotter?
ScholarIQh-index
Ricardo Correa‐Rotter has an h-index of 53 in OpenAlex.
What is the i10-index of Ricardo Correa‐Rotter?
ScholarIQi10-index
Ricardo Correa‐Rotter has an i10-index of 141 in OpenAlex.
What is the ORCID of Ricardo Correa‐Rotter?
ScholarIQorcid
The ORCID for Ricardo Correa‐Rotter is on the source record.
What is the OpenAlex record for Ricardo Correa‐Rotter?
ScholarIQopenalex
The OpenAlex for Ricardo Correa‐Rotter is on the source record.
What are the most-cited papers on Ricardo Correa‐Rotter?
ScholarIQmost cited works
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Johannes F.E. Mann, John J.V. McMurray, Magnus Lindberg, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna-Maria Langkilde, David C. Wheeler
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort, Ricardo Correa‐Rotter, Brenda R Hemmelgarn, Tazeen H. Jafar, Hiddo J.L. Heerspink, Johannes F.E. Mann, Kunihiro Matsushita, Chi Pang Wen
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Adeera Levin, Marcello Tonelli, Joseph V. Bonventre, Josef Coresh, Jo‐Ann Donner, Agnes B. Fogo, Caroline S. Fox, Ron T. Gansevoort, Hiddo J.L. Heerspink, Meg Jardine, Bertram L. Kasiske, Anna Köttgen, Matthias Kretzler, Andrew S. Levey, Valérie A. Luyckx, Ravindra L. Mehta, Orson W. Moe, Gregorio T. Obrador, Neesh Pannu, Chirag R. Parikh, Vlado Perkovic, Carol A. Pollock, Peter Stenvinkel, Katherine R Tuttle, David C. Wheeler, Kai‐Uwe Eckardt, Dwomoa Adu, Sanjay Kumar Agarwal, Mona Alrukhaimi, Hans‐Joachim Anders, Gloria Ashuntantang, Shakti Basnet, Aminu K. Bello, Worawon Chailimpamontree, Ricardo Correa‐Rotter, Jonathan C. Craig, Walter Douthat, Harold I. Feldman, Mohammad Reza Ganji, Guillermo García-García, Mohammed Benghanem Gharbi, David C.H. Harris, Vivekanand Jha, David W. Johnson, Rümeyza Kazancıoğlu, Robyn G. Langham, Zhi-Hong Liu, Ziad A. Massy, Masaomi Nangaku, Robert G. Nelson, Dónal O’Donoghue, Ikechi G. Okpechi, Roberto Pecoits‐Filho, Neil R. Powe, Giuseppe Remuzzi, Charlotte Roberts, Jérôme Rossert, Laura Solá, Bénédicte Stengel, Ernest K. Sumaili M, Yusuke Suzuki, Tetsuhiro Tanaka, Sajja Tatiyanupanwong, Bernadette Thomas, Katrin Uhlig, Robert G. Walker, S. L. White, Andrzej Więcek, Chih-Wei Yang
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits‐Filho, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink